Biomerica, Inc. (BMRA)
Automate Your Wheel Strategy on BMRA
With Tiblio's Option Bot, you can configure your own wheel strategy including BMRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMRA
- Rev/Share 0.3316
- Book/Share 0.3232
- PB 9.7766
- Debt/Equity 0.0981
- CurrentRatio 3.7623
- ROIC -0.8398
- MktCap 8044602.0
- FreeCF/Share -0.2481
- PFCF -1.8937
- PE -11.1554
- Debt/Assets 0.0736
- DivYield 0
- ROE -0.859
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Mr. Chin brings over 20 years of financial experience across public and private healthcare organizations Mr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financing Mr.
Read More
Biomerica's inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced diagnostic-guided therapies, today announced that data from its pivotal clinical trial evaluating the inFoods® IBS test in treating IBS sufferers has been published in the June 2025 issue of Gastroenterology , the official journal of the American Gastroenterological Association and the highest-impact publication in the GI field.
Read More
Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), an innovator in diagnostic-guided therapy, today announced compelling real-world results demonstrating the effectiveness of its inFoods® IBS product, along with the launch of a proprietary real-time patient feedback system to enhance symptom tracking and improve patient outcomes.
Read More
PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test.
Read More
About Biomerica, Inc. (BMRA)
- IPO Date 1984-09-07
- Website https://www.biomerica.com
- Industry Medical - Devices
- CEO Mr. Zackary S. Irani
- Employees 64